Cytochrome P450 activity and its alteration in different diseases;Actividad del citocromo P450 y su alteración en diversas patologías

Revista Medica de Chile

Volumn 132, Issue 1, 2004, Pages 85-94

  Orellana B, Myriam ^a,b   Guajardo T, Viviana ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Cytochrome P450; Enzyme induction; Xenobiotics

Indexed keywords

CYTOCHROME P450; LIVER ENZYME; OXYGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

CATALYST; CELL TYPE; DIABETES MELLITUS; DRUG CLEARANCE; DRUG TOXICITY; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME REGULATION; ENZYME REPRESSION; ENZYME SPECIFICITY; HUMAN; HYPERTENSION; INFECTION; INFLAMMATORY DISEASE; LIVER DISEASE; METABOLISM; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; XENOBIOTIC METABOLISM;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE; HUMANS; LIVER; NADP; XENOBIOTICS;

EID: 12544260518     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. WINTERS DK, CEDERBAUM AI. Biochemistry of Cytochrome P450. In Hepatic and bile secretion: Physiology and pathophysiology 1993, edited by Tavaloni and PD Berk. Raven Press, Ltd., New York. Chapter 27, 407-20.
2. DING X, KAMINSKY LS. Human extrahepatic cytochromes p450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003; 43: 149-73.
3. GOEPTAR AR, SHEERENS H, VERMEULEN NPE. Oxygen and xenobiotic reductase activities of cytochrome P450. Crit Rev Toxicol 1995; 25: 25-65.
4. CAPDEVILA J, HARRIS RC, FALCK JR. Microsomal cytochrome P450 and eicosanoid metabolism. Cell Mol Life Sci 2002; 59: 780-9.
5. HARDER DR, CAMPBELL WB, ROMAN RJ. Role of cytochrome P450 enzymes and metabolites of arachidonic acid in the control vascular tone. J Vasc Res 1995; 32: 79-92.
6. OMURA T, SATO R. The carbon-monoxide binding pigment by liver microsomes. J Biol Chem 1964, 239: 2379-85.
7. COON MJ, DING X, PERNECKY SJ, VAZ ADN. Cytochrome P450: progress and predictions. FASEB J 1992; 6: 669-73.
8. GUENGERICH FP. Cytochromes P450 of human liver. Classification and activity profiles of the major enzymes. In: Advances in drug metabolism in man. Pacifici GM & Fracchia GN (eds) European Commission. Office for the Official Publications of the European Communities, Luxenbourg 1995; 179-231.
9. GUENGERICH P. Uncommon P450 catalysed reactions. Curr Drug Metabolism 2001; 2: 93-115.
10. HOLLENBERG PF. Mechanism of cytochrome p450 and peroxidase catalysed xenobiotic metabolism. FASEB J 1992; 6: 686-94.
11. OMURA T. Forty years of Cytochrome P450. Biochem Biophys Res Commun 1999; 266: 690-8.
12. NELSON DR, KOYMANS L, KAMATAKI T, STEGEMAN JJ, FEYEREISEN R, WAXMAN DJ ET AL. P450 superfamily. Up date of new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
13. DIERKS E, STAMS K, LIM HK, CORNELIUS G, ZHANG H, BALI. S. A method for the simultaneous evaluation of the activities of seven major human drug metabolizing cytochrome P450s using in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 2001; 99: 23-9.
14. YUAN R, MADANI S, WEI X, REYNOLDS K, HUANG SM. Evaluation of cytochrome p450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 2002; 30: 1311-9.
15. LIN JH, LU A. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinetic 1998; 35: 361-90.
16. WHITLOCK JPJ. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 1999; 39: 103-25.
17. LIEBER CS. Cytochrome P4502E1: its physiological and pathological role. Physiol Rev 1997; 77: 517-44.
18. RONIS MJJ, LINDROS KO, INGELMAN-SUNDBERG M. The CYP2E subfamily. In: Cytochromes P450: Metabolic and Toxicological Aspects. Ioannides C & Parke DV eds. CRC Press, Boca Raton, 1996; 211-39.
19. CHENG P, MORGAN E. Hepatic cytochrome p450 regulation in disease states. Current Drug Metabolism 2001; 2: 165-83.
20. LUCAS D, FAREZ C, BARDOU LG, VAISSE J, ATTALI JR, VALENSI P. Cytochrome p450 2E1 in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 1998; 12: 553-8.
21. POMPOSIELLO SI, CARROLL MA, FALCK JR, MCGIFF JC. Epoxyeicosatrienoic acid-mediated renal vasodilatation to arachidonic acid is enhanced in SHR. Hypertension 2001; 37: 887-92.
22. FARRELL G. Effects of disease on expression and regulation of CYPs. Mol Aspects Med 1999; 20: 55-70.
23. ROMAN R. P450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131-85.
24. IMIG JD. Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol 2000; 279: F965-F981.
25. PARMENTIER JH, MUTHALIF MM, NISHIMOTO AT, MALIK KU. 20- hydroxyeicosatetraenoic acid mediates angiotensin II-induced phospholipase D activation in vascular smooth muscle cells. Hypertension 2001; 37: 623-32.
26. LASKER JM, CHEN WB, WOLF I, BLOSWICK BP, WILSON PD, POWELL PK. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of CYP 4F2 and CYP 4A11. J Biol Chem 2000; 275: 4118-26.
27. CATELLA F, LAWSON JA, FITZGERALD DJ, FITZGERALD GA. Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy induced hypertension. Proc Natl Acad Sci (USA) 1990; 87: 5893-7.
28. MAIER K, HENDERSON L, NARAYANAN J, ALONSO GALICIA M, FALCK JR. Fluorescent HPLC assay for 20 HETE and other p450 metabolites of arachidonic acid. Am J Physiol Heat Circ Physiol 2000; 279: H863-H871.
29. LAFFER CL, LANIADO-SCHWARTZMAN M, WANG MH, NASJLETTI A, ELIJOVICH F. Differential regulation of natriuresis by 20-hidroxyeicosatetraenoic acid in human salt sensitive versus salt resistant hypertension. Circulation 2003; 107: 574-8.
30. MORGAN ET. Regulation of cytochrome P450 by inflammatory mediators: Why and how? Drug Metab Dispos 2001; 29: 207-12.
31. BARCLAY TB, PETERS JM, SEWER MB, FERRARI L, GONZÁLEZ FJ, MORGAN ET. Modulation of cytochrome P450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator activated receptor alpha dependent. J Pharmacol Exp Ther 1999; 290: 1250-7.
32. PALMER CN, HSU MH, GRIFFIN KJ, RAUCY JL, JOHNSON EF. Peroxisome proliferator activated receptor alpha expression in human liver. Mol Pharmacol 1998; 53: 14-22.
33. KRAEMER MJ, FURUKAWA CT, KOUP JR, SHAPIRO GG, PERSON WE, BIERMAN CW. Altered theophylline clearence during an influenza B outbreak. Pediatrics 1982; 69: 476-80.
34. MIRGHANI RA, HELLGREN U, WESTERBERG PA, ERICSSON O, BERTILSSON L, GUSTAFSSON LL. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clin Pharmacol Ther 1999; 66: 454-60.
35. OKUNO H, TAKASU M, KANO H, SEKI T, SHIOZAKI Y, INOUE K. Depression of drug metabolizing activity in the human liver by interferon beta. Hepatology 1993; 17: 65-9.
36. SHIMOJO N. Cytochrome P450 changes in rats with streptozocin induced diabetes. Int J Biochem 1994; 26: 1261-8.
37. DONAHUE BS, SKOTTNER-LUNDIN A, MORGAN ET. Growth hormone dependent and independent regulation of cytochrome P450 isozyme expression in streptozotocin diabetic rats. Endocrinology 1991; 128: 2065-76.
38. ROBERTSON G, LECLERCQ I, FARRELL GC. Non alcoholic steatosis and steatohepatitis II. Cytochrome P450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001; 281: 1135-9.
39. KROETZ DL, YOOK P, COSTET P, BIANCHI P, PINEAU T. Peroxisome proliferator activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem 1998; 273: 31581-9.
40. KORRAPATI MR, VESTAL RE, LOI CM. Theophylline metabolism in healthy non smokers and in patients with insulin dependent diabetes mellitus. Clin Pharmacol Ther 1995; 57: 413-8.
41. ENRÍQUEZ A, LECLERCQ I, FARRELL GC, ROBERTSON G. Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem Biophys Res Commun 1999; 255: 300-6.
42. FRIEDMAN JM, HALAAS JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70.
43. LECLERCQ IA, FIELD J, ENRÍQUEZ A, FARRELL GC, ROBERTSON GR. Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice. Biochem Biophys Res Commun 2000; 268: 337-44.
44. LUCAS D, FERRARA R, GONZÁLEZ E, BODENEZ P, ALBORES A, MANNO M, BERTHOU F. Chlorzoxazone, a selective probe for phenotyping cyp2E1 in humans. Pharmacogenetics 1999; 9: 377-88.
45. NIEMELA O, PARKKILA S, JUNOVEN RO, VITALA K, GELBOIN HV, PASANEN M. Cytochrome P450 2A6, 2E1, and 3a, and production of protein-aldehyde adducts in the liver of patients with alcoholic and non alcoholic liver diseases. J Hepatol 2000; 33: 893-901.
46. WELTMAN MD, FARRELL GC, HALL P, INGELMAN-SUNDBERG M, LIDDLE C. Hepatic cytochrome P4502E1 is increased in patients with non alcoholic steatohepatitis. Hepatology 1998; 27: 128-33.